The lawsuit claims that three major healthcare companies were pushing up the price of insulin by 1,200 percent.

On Tuesday, the Federal Trade Commission (FTC) released its second interim staff report on prescription drug middlemen. The report examines the impact of PBMs (specifically CVS Caremark ...

Pharmacy benefit managers overcharged for specialty generic medications — in many cases by hundreds and thousands of percent ...

The term Web Client Runtime Security (WCRS) was coined by the authors to highlight the security or possible malicious behavior of the code executed in users' browsers during their web interactions.

In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.

The FTC analyzed data for 51 specialty generic drugs dispensed from 2017-2022 for patients with commercial insurance or Medicare Part D plans managed by CVS Caremark, Express Scripts and OptumRx.

FTC Chair Lina Khan has the big three pharmacy benefit managers in sight—UnitedHealth's OptumRx, Cigna's Express Scripts and CVS Caremark Rx. © 2024 Fortune Media ...

The Federal Trade Commission said three top pharmacy suppliers made profits of 7,700 percent on a lifesaving hypertension ...

The Federal Trade Commision (FTC) found prescription benefits managers like UnitedHealth's OptumRX have gained $7.3B from ...

FTC said the "Big 3 PBMs" — CVS’s Caremark, Cigna’s Express Scripts, and UnitedHealth’s OptumRx — imposed markups of hundreds to thousands of percent on critical drugs, including those ...

The FTC released a 60-page report Tuesday targeting the biggest three pharmacy benefit managers, claiming the companies hiked ...

The FTC’s findings—which analyzed 51 specialty generic drugs from 2017 to 2022—showed these pharmacy benefit managers’ (PBMs') affiliated pharmacies spun up $7.3 billion in excess revenue ...